aripiprazole, Abilify (cont.)

Pharmacy Author:
Medical Editor:
Medical and Pharmacy Editor:


Long-term use of aripiprazole may lead to a potentially irreversible condition called tardive dyskinesia (involuntary movements of the jaw, lips, and tongue).

A potentially fatal complex referred to as neuroleptic malignant syndrome has been reported with anti-psychotic drugs, including aripiprazole. Patients who develop this syndrome may have:

  • high fevers,
  • muscle rigidity,
  • altered
  • mental status,
  • irregular pulse or blood pressure,
  • rapid heart rate,
  • excessive sweating, and
  • heart arrhythmias.

All atypical antipsychotic drugs have been associated with metabolic changes such as hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Serious cases of hyperglycemia leading to coma or death have been reported in patients treated with atypical antipsychotics. Although there is no clear link between aripiprazole and diabetes, patients should be tested during treatment for elevated blood-sugars. Additionally, persons with risk factors for diabetes, including obesity or a family history of diabetes, should have their fasting levels of blood sugar tested before starting treatment and periodically throughout treatment to detect the onset of diabetes. Any patient developing symptoms that suggest diabetes during treatment should be tested for diabetes.

Elderly patients with dementia related psychosis treated with antipsychotics are at an increased risk of death and aripiprazole should not be used for this indication.

Antidepressants increased the risk of suicidal thinking and behavior in short-term studies in children and adolescents with depression and other psychiatric disorders. Anyone considering the use of aripiprazole or any other antidepressant in a child or adolescent must balance this risk of suicide with the clinical need. Patients who are started on therapy should be closely observed for clinical worsening, suicidal thoughts, or unusual changes in behavior.




  • Tablets: 10, 15, 20, and 30 mg.
  • Tablets (Disintegrating): 10 and 15 mg.
  • Oral solution: 1 mg/mL.
  • Injection Solution: 9.75 mg/1.3 ml (7.5 mg/ml)
  • Extended release Injection: 300 or 400 mg/vial
Medically Reviewed by a Doctor on 4/13/2015

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index